Edwards Lifesciences (NYSE:EW) is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York on September 13, 2011. The company’s CEO, Michael A. Mussallem, will talk about the company at the conference.
Investor focus is currently on Edwards as its Sapien transcatheter heart valve (THV) is under review by the US Food and Drug Administration. The company expects to receive approval for Cohort B (inoperable patients) by October 2011. Earlier, in July 2011, Edwards had received favorable recommendation from the FDA advisory panel for Sapien THV.
This endorsement will help the treatment of patients with severe aortic stenosis and those deemed unfit for conventional open-heart valve surgery (Cohort B). Although the panel voted in favor (9-0 with one abstention) of the device, they are concerned about vulnerability to neurological problems, particularly stroke in patients treated with Sapien.
With respect to effectiveness (9-1) and safety (7-3), the panel upheld Sapien. The launch, anticipated in the fourth quarter is expected to result in $20-$25 million of sales during the first quarter and $150-$250 million in the first full year.
However, the number of targeted centers in US in the first year was reduced to 150-200 (apart from the 25 clinical trial sites) from the previous guidance of 200-400. This change was made to fulfill FDA’s recommendation of more patients being treated in each center so that the rollout is tracked properly. Edwards is also working to secure reimbursement for the product.
The development of Sapien products holds immense potential for Edwards as it provides surgeons the option to eliminate the possibility of open heart procedures. Continued adoption of the new 29 mm Sapien XT valve in Europe led to a 60% rise in THV sales to $85.3 million during the quarter.
Based on robust performance so far, Edwards has raised its THV sales guidance for 2011. However, the company operates in a highly competitive environment in the midst of players such as Medtronic (NYSE:MDT) and Boston Scientific (NYSE:BSX). Besides, any hiccup in the approval process of Sapien would be a major setback for the company.
We currently have a Neutral recommendation on Edwards, which also corresponds to a Zacks #3 Rank (Hold) in the short term.
http://www.dailymarkets.com/stock/2011/09/08/ew-ceo-to-speak-at-global-conference/
Recent EW News
- ONE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR ENDOTRONIX CORDELLA PULMONARY ARTERY SENSOR SYSTEM • PR Newswire (US) • 09/28/2024 09:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 12:17:49 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 09:25:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 10:06:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 11:10:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 08:34:20 PM
- Edwards Lifesciences Completes Sale of Critical Care • Business Wire • 09/03/2024 08:30:00 PM
- CORRECTING and REPLACING First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves • Business Wire • 08/31/2024 10:58:00 PM
- First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves • Business Wire • 08/31/2024 04:35:00 PM
- Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference • Business Wire • 08/21/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 11:42:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 09:12:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 08:33:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 09:58:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 08:19:52 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/31/2024 08:20:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 08:14:58 PM
- Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5% • IH Market News • 07/25/2024 10:19:48 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:26:30 PM
- Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix • Business Wire • 07/24/2024 08:15:00 PM
- Edwards Lifesciences Reports Second Quarter Results • Business Wire • 07/24/2024 08:15:00 PM
- Edwards Lifesciences to Host Earnings Conference Call on July 24, 2024 • Business Wire • 07/17/2024 11:05:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 01:04:03 PM
- Edwards Lifesciences to Acquire Innovalve • Business Wire • 07/15/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:38:23 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM